Welcome to our dedicated page for Genenta Science Spa news (Ticker: GNTA), a resource for investors and traders seeking the latest updates and insights on Genenta Science Spa stock.
Genenta Science S.p.A. (NASDAQ: GNTA) is a clinical-stage immuno-oncology company developing Temferon™, a hematopoietic stem cell therapy platform aimed at solid tumor cancers. The GNTA news feed on Stock Titan aggregates company-issued updates, regulatory disclosures, and other coverage that shed light on how this platform is progressing through clinical development and corporate milestones.
News about Genenta frequently centers on its Temferon clinical programs, including the TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT gene promoter and Phase 1/2a work in metastatic renal cell carcinoma and other genitourinary tumors. Company releases discuss survival trends, long-term follow-up observations, and exploratory immune findings related to tumor microenvironment reprogramming and T cell responses.
Investors following GNTA can also expect coverage of financing transactions such as registered direct offerings of American Depositary Shares, mandatory convertible bond financings with institutional partners, and the use of at-the-market facilities, as well as updates on cash and short-term investments in the context of funding clinical trials. Additional news items highlight strategic collaborations with organizations like Anemocyte and AGC Biologics for plasmid DNA and cell therapy manufacturing, along with participation in biotech conferences and sector events.
Corporate governance and leadership developments, including board appointments, changes in executive roles, amendments to by-laws, and disclosures about insider share ownership, are also reported through Genenta’s press releases and Form 6-K filings. For readers tracking GNTA stock, this news page provides a centralized view of the company’s clinical, financial, and strategic updates. Bookmark the GNTA news section to review new releases and historical announcements as Genenta advances its immuno-oncology platform.
Genenta Science (Nasdaq: GNTA), transforming into Saentra Forge (Nasdaq: SAEN), announced appointment of Paolo Salvato to the Board of ATC, marking its first entry into defense manufacturing, and confirmed ongoing evaluation of majority-control acquisitions in regulated national-security sectors. Nature Medicine accepted a manuscript reporting key clinical findings from the company’s Glioblastoma multiforme trial, with publication expected in the coming weeks.
Management said it is prioritizing profitable, majority-controlled industrial scale-ups and evaluating biotech partnerships to reduce capital needs for registrational studies, while retaining flexibility to access U.S. public markets subject to market and regulatory conditions.
Genenta Science (Nasdaq: GNTA) is transforming into an industrial consolidator focused on biotech, defense, aerospace, and national security and intends to adopt the new name Saentra Forge S.p.A with a planned Nasdaq ticker of SAEN. The company has begun execution by funding a staged, performance-based acquisition of ATC, a precision weapons manufacturer, with total funding expected of EUR 5.1 million. ATC forecasts ~€4.0M revenue and >€2.0M EBITDA in 2026, rising to ~€9.0M and roughly double EBITDA in 2027. The Praexidia Foundation joined as a long-term shareholder under a five-year lock-up. The company expects cash and marketable securities of ~$33M at Dec 31, 2025 and has engaged DC Advisory for biotech partnering.
Genenta Science (Nasdaq: GNTA) updated ownership details for CEO and co-founder Pierluigi Paracchi as of December 19, 2025. The company reports Mr. Paracchi has acquired 30,000 ADSs over time via open-market purchases and has not reported any sales in SEC filings. In total, he owns 2,326,129 ADSs and ordinary shares, representing approximately 10% of Genenta’s outstanding share capital as calculated under SEC rules.
The disclosure indicates founder insider accumulation and a sizable single-holder stake that investors may consider when evaluating free float and insider alignment.
Genenta Science (Nasdaq: GNTA) reported a November 21, 2025 data cut from its TEM-GBM study in newly diagnosed glioblastoma patients with unmethylated MGMT. As of the cut, 25 patients treated with Temferon showed 44% 18‑month survival (vs 38% in April), a 2‑year survival of 29%, and median overall survival of 17 months, all consistent with prior updates. Historical uMGMT benchmarks cited: ~14% two‑year survival and 13–15 months median OS. One patient reached 39 months post‑surgery without intervening therapy and completed a 3.5‑year follow‑up. Findings include preliminary immune evidence that bone‑marrow‑derived myeloid cells can reach tumor tissue to deliver payloads. The company held approximately $30 million in cash and short‑term investments as of November 1, 2025.
Genenta Science (Nasdaq: GNTA) announced a registered direct offering to sell 4,285,715 ADSs at $3.50 per ADS for gross proceeds of approximately $15.0 million, before fees and expenses. Maxim Group is lead placement agent and Rodman & Renshaw is co-placement agent. Genenta intends to use net proceeds for working capital and general corporate purposes. The offering is expected to close on or about October 28, 2025, subject to customary closing conditions and a prospectus supplement to be filed under its effective Form F-3 registration.
Genenta Science (Nasdaq: GNTA) and ANEMOCYTE announced an expanded strategic collaboration on an off-the-shelf lentiviral vector (LVV) Plasmid DNA technology platform, dated October 24, 2025. The agreement builds on an existing partnership and makes Genenta's clinically validated LVV Plasmid DNA platform, originating from research by Professor Luigi Naldini, available to ANEMOCYTE and its clients.
The collaboration aims to supply top-quality plasmid DNA across R&D to GMP grade and from preclinical to commercial stages, supporting scalable advanced therapy program development and broadening ANEMOCYTE's offering to customers.
Genenta Science (Nasdaq: GNTA) has reported promising long-term follow-up data from its TEM-GBM study of Temferon in glioblastoma multiforme patients. The study enrolled 38 patients, with 25 receiving Temferon. Two significant milestones were achieved with two patients surviving three years from initial surgery in the TEM-LT long-term follow-up study.
Key clinical outcomes include a 29% two-year survival rate for unmethylated MGMT patients, with median overall survival at 17 months, comparing favorably to historical cohorts showing approximately 14% two-year survival and 13-15 months median survival with standard care.
The company has also initiated the TEM-GU Phase 1 study for genitourinary tumors, targeting 12 patients with Metastatic Renal Cell Carcinoma. The trial will evaluate Temferon's combination potential with immune checkpoint inhibitors or tyrosine kinase inhibitors. Additionally, a scientific manuscript demonstrating Temferon's potential in enhancing CAR-T activity has been accepted for publication in Science Translational Medicine.
Genenta Science (NASDAQ: GNTA) has announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. The company's Chief Medical Officer, Carlo Russo, will be available for one-on-one meetings from 9:00 A.M. to 3:00 P.M. (ET). Interested parties can schedule meetings by contacting John Perez at jperez@dboralcapital.com.
Genenta Science (GNTA) has announced a strategic collaboration with Anemocyte, an Italian Biotech Manufacturing Organization (BMO), for the production of critical starting materials for cell-based therapies. The partnership involves the successful establishment of Cell Banks and manufacturing of Plasmids for viral vector production. Anemocyte's expertise has been crucial in supporting Genenta's clinical trials progression through high-quality manufacturing processes. The collaboration highlights the synergy between Genenta's immuno-oncology platform and Anemocyte's manufacturing capabilities, with Genenta being notably recognized as the first Italian company listed on Nasdaq.
Genenta Science (Nasdaq: GNTA) announced its upcoming presentation at the 'Montalcini Global Biotech Tour' in Doha, Qatar on April 17th, 2025. The presentation follows two significant financial developments:
1. A €20 million ($22.7 million) strategic financing through a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB), aimed at advancing Temferon™ in metastatic Renal Cell Cancer (mRCC)
2. An additional €3.0 million ($3.2 million) raised via an at-the-market (ATM) facility
The event will be hosted by Qatar's Minister of State for Foreign Trade Affairs and Italy's Minister of Health, featuring presentations from key stakeholders including Qatar Research, Development and Innovation Council (QRDI) and potential meetings with Qatar Investment Authority (QIA), which manages over $475 billion in assets.